江苏迈度

Jiangsu Maidu Drug Development is a clinical-stage biopharmaceutical company headquartered in Taizhou, China, specializing in the discovery and development of novel small molecule therapeutics. The company's primary research focus is on metabolic diseases, particularly hyperuricemia, gout, and type 2 diabetes, with additional interests in oncology. Its lead candidate, MD-001, is a selective URAT1 inhibitor currently undergoing Phase 2 clinical trials for the treatment of hyperuricemia and gout. Maidu Pharma operates out of the China Medical City (CMC) and leverages a robust R&D platform to advance its pipeline of proprietary drug candidates. The company is committed to addressing unmet medical needs through the development of high-quality, innovative medicines for the global market.